GlassScriptPhysician profile
Elliot A Heller
NPI 1043383789
$10,432.35
in general payments reported to CMS, 2019-2025
39 companies · $1,822 in 2025
The $1,822 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $797 · 2021: $1,748 · 2022: $1,547 · 2023: $1,297 · 2024: $1,776 · 2025: $1,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,855 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,854.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,912.90 | 2019-2025 | |
| Janssen Biotech, INC. | $1,416.52 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,384.74 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,147.48 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $897.41 | 2019-2025 | Vemlidy |
| Madrigal Pharmaceuticals | $642.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $372.57 | 2019-2025 | |
| Celgene Corporation | $296.53 | 2019-2023 | Zeposia |
| Genzyme Corporation | $263.34 | 2022-2025 | |
| Ardelyx, INC. | $256.28 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $154.15 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $148.39 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $146.61 | 2025 | |
| Redhill Biopharma INC. | $142.40 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $137.89 | 2019-2024 | Dificid |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.